Patrys Limited · ASX:PAB
Patrys — Shareholder Meeting (November 2008)
29 slides from Patrys's shareholder meeting presentation, Nov 27, 2008
Slide 1: Natural Human Antibodies to Treat Human Diseases
For personal use only ASX: PAB Natural Human A tib di to Antibodies t Treat T t Human Diseases Annual General Meeting 28 November 2008 Chief Executive Officer Presentation Daniel K. Devine
Slide 2: Safe harbor
Safe harbor For personal use only The following material is for general information purposes only and is not to be relied upon for the making of an investment decision. Any investment in Patrys Limited ACN 123 055 363 (Patrys) is subject to investment risk including the possibility of loss of capita
Slide 3: Agenda
Agenda For personal use only Company overview CY08 major accomplishments Natural human antibodyy technologies g Patrys products – market positioning Pipeline Clinical candidates: PAT‐LM1 and PAT‐SM6 Partnering activities Market demand for antibody products CY09 milestones Appendi
Slide 4: Patrys overview
Patrys overview For personal use only Natural human antibodies offer potential advantages in Product advantages US$20 billion antibody therapy market Patrys products target cancers with mortality rates >80%; Market focus medical & industry demand is high Facilitates internal development and partneri
Slide 5: CY08 major accomplishments
CY08 major accomplishments For personal use only Nov Primate safety study Commenced production of PAT‐LM1 and PAT‐SM6 for final ’08 production preclinical primate safety studies to commence shortly Nov New forms of lead New forms of lead products (fragments/IgGs) generated and active ‘08 products ag
Slide 6: Natural human antibody platform
Natural human antibody platform For personal use only 6
Slide 7: Patrys products: potential benefits
Patrys products: potential benefits For personal use only Antibodies on market from non‐ F t Factor P t natural Patrys t l human h antibodies tib di human sources Interfere with function of healthy Do not attack healthy tissues Safety cells and tissues screened Absorbed by healthy tissues –
Slide 8: Patrys products: long-term franchises
Patrys products: long‐term franchises For personal use only Antibodies in Category Disease target Antibody clinic to same disease target* CD20 Rituxan 10 Anti cancer antibodies Anti-cancer EGFR Erbitux 12 w/>US$1 billion per HER2 Herceptin 9 year in sales VEGF Avastin 5 GRP78** GRP78 PAT-SM6 PAT SM6
Slide 9: Patrys products: unmet medical needs
Patrys products: unmet medical needs For personal use only Antibody sales Antibodies have had particular market success Four oncologygy antibodies exceed US$1 billion in sales per year, but limited in applications Five Year Mortality Rates Cancers targeted by Patrys continue to represent signi
Slide 10: Pipeline: diversified product portfolio
Pipeline: diversified product portfolio For personal use only Diversified products ‐ each product attacks cancer in unique manner Depth facilitates internal development and partnering Portfolio in a single company 10
Slide 11: PAT-SC1: human clinical trial
PAT‐SC1: human clinical trial For personal use only Probability of Survival 100% 35 Treated Patients Treated patients had higher Effective 90% survival rate 80% Well tolerated; tolerated no major Safe adverse reactions 70% Low dose Dose < 10% of marketed anti‐ 60% – low cost cancer antibodies 50% Ou
Slide 12: Clinical candidates: PAT-LM1/PAT-SM6
Clinical candidates: PAT‐LM1/PAT‐SM6 For personal use only Factor PAT‐LM1 and PAT‐SM6 profiles Promising therapeutic POC Efficacy in multiple preclinical animal studies potential and advantages over Markets 90% to 98% patients across many cancers existing products Safe S f profile: fil human
Slide 13: PAT-SM6/PAT-LM1: production
PAT‐SM6/PAT‐LM1: production For personal use only Antibody Production ‐ Grams Per Litre For Phase I staged products products, industry targets 1 gram per litre 2 as indication of commercial yield 1.8 1.6 Goal achieved for two clinical 1.4 candidates 1.2 Targeted Commercial Threshold ‐ Phase I
Slide 14: PAT-SM6/PAT-LM1: prevent spread of cancer
PAT‐SM6/PAT‐LM1: prevent spread of cancer For personal use only Animals Developing Colon Cancer Metastases (n 20) (n=20) PAT‐LM1 PAT LM1 shown effective in animal 85% models testing ability to prevent 90% spread of colon cancer metastases 80% 70% In targeted cancers, most deaths 60% result from
Slide 15: PAT-LM1 & PAT-SM6: Cancer Stem Cells
PAT‐LM1 & PAT‐SM6: Cancer Stem Cells For personal use only Tumours are heterogenous – small population of “stem cells“ that cause regeneration of tumour Literature: correlation between anti‐stem cell activity and therapeutic potential of products Key attribute of antibody company OncoMed Pharm
Slide 16: PAT-LM1: disease target discovery
PAT‐LM1: disease target discovery For personal use only Cell surface target expressed on cancer tissues; p not expressed on healthyy tissues screened Expressed in human prostate cancer tissue Contributes to tumour ggrowth and progression p g in breast cancer Strongly correlated with vascular
Slide 17: Partnering strategy
Partnering strategy For personal use only Balanced approach of internal development and partnering still applies Patrys has placed higher premium on partnering transactions Advance leads to clinic; ensure trials designed to drive partnering 17
Slide 18: Partnering – existing collaborations
Partnering – existing collaborations For personal use only AstraZeneca st a e eca – PAT‐SC1: SC Transaction completed by predecessor company to Patrys AZ has exclusive rights to develop PAT‐SC1 Patrys y earns revenue w/successful achievement of milestones byy AZ Debiopharm – exclusive righ
Slide 19: Driving partnering value - I
Driving partnering value ‐ I For personal use only Data points identified d f d as d driving value l in antibody transactions: Proprietary P i t di disease targets t t with ith reported t d association i ti with ith cancer Product ability to target primary tumour and spread of cancer Ability
Slide 20: Driving partnering value - II
Driving partnering value ‐ II For personal use only Jul Nov Key partnering data points ‘07 ‘08 Industry demand for your technologies/products √ √ R&D activities Completely human antibodies? √ √ designed to generate value to Multiple promising products available for partnering? √ √+ prospective par
Slide 21: CY08: demand for antibody products
CY08: demand for antibody products For personal use only Value US$ Licensor Licensee Date Stage g Disease millions Sanofi-Aventis Crucell 08-Jan Phase I Rabies $124 GSK EUSA 08-Feb Preclinical Various $44 Sanofi-Aventis Dyax Corp 08-Feb Preclinical Oncology $125 Amgen Takeda 08-Feb Phase I/II Variou
Slide 22: CY09 – driving shareholder value
CY09 – driving shareholder value For personal use only Partnering Clinical Develop Pipeline Expansion Current market attributes Other New New New Takeda PAT‐LM1 PAT‐SM6 PAT‐LM1 no material value to Leads Leads g Targets Forms technology h l andd products d 4QCY08 Announce Animal Animal safety safe
Slide 23: Thank You
For personal use only Thank You 23
Slide 24: Appendix: CY08 R&D data sampling
Appendix: CY08 R&D data sampling For personal use only 24
Slide 25: CY08 R&D: new disease targets
CY08 R&D: new disease targets For personal use only Target Third party literature reports EExpressedd iin human h prostate t t cancer tissue ti R&D expansion increased Alteration may contribute to tumour growth and new target output from 1 PAT‐ progression in breast cancer every two years to 3
Slide 26: CY08 R&D: preclinical animal studies
CY08 R&D: preclinical animal studies For personal use only Animals with Gastric Cancer Minimal Residual Disease in Bone Marrow and Multiple products shown effective in Blood (n = 20 per group) preclinical animal studies testing ability to prevent spread of cancer 50% 50% In targeted cancers, mos
Slide 27: CY08 R&D: commercial production
CY08 R&D: commercial production For personal use only Antibody Production ‐ Grams Per Litre In addition to reaching commercial yields for PAT‐LM1 2.5 and PAT‐SM6, PAT‐CM1 now at commercial level 2 Technology approach developed 1.5 has ggeneral application pp across pipeline Targeted Commercial T
Slide 28: CY08 R&D: new forms of leads - I
CY08 R&D: new forms of leads ‐ I For personal use only Alternative forms: Antibodies come in different forms (e.g., fragments, IgMs, IgGs) Forms can vary by size, binding sites, interaction with other elements of human immune system All forms recognise and bind to same target on cancer cell
Slide 29: CY08 R&D: new forms of leads - II
CY08 R&D: new forms of leads ‐ II For personal use only Product PAT‐SM6 PAT‐LM1 PAT‐PM2 PAT‐NM2 PAT‐NM2 Form Fragment IgG IgG IgG IgG Cancer Type Pancreatic Lung Lung Lung Gastric Experiment Confocal FACS FACS FACS IHC Data Examples Lead Active Forms Patrys has now generated additional forms of 7